Insider Transactions in Q1 2021 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
827
-100.0%
|
$14,886
$18.09 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
227
-1.92%
|
$4,086
$18.16 P/Share
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+4.46%
|
-
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.16%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.87%
|
-
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.04%
|
$17,334
$18.16 P/Share
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.78%
|
-
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-33.84%
|
$7,614
$18.16 P/Share
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 08
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,571
-100.0%
|
$67,849
$19.66 P/Share
|